CIRM Clinical Trials
Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.
0
CIRM-Funded Clinical Trials
Disease Areas | Investigator | Organization | Phase | Trial Status | Target Enrollment | Detail |
---|---|---|---|---|---|---|
B cell cancers Leukemia |
Thomas J Kipps | University of California, San Diego | Phase 1/2 | Active, not recruiting | 102 | |
Pediatrics Sickle Cell Disease |
Dr. Donald B. Kohn PhD | University of California, Los Angeles | Phase 1 | Active, not recruiting | 4 | |
HIV-related Lymphoma HIV/AIDS |
Dr Mehrdad Abedi | University of California, Davis | Phase 1/2 | Active, not recruiting | 11 | |
HIV/AIDS | Prof. John A. Zaia | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 12 | |
Kidney Failure | Dr Robert Lowsky | Stanford University | Phase 1 | Active, not recruiting | 15 | |
Kidney Failure | Jeffrey Lawson | Humacyte, Inc. | Phase 3 | Active, not recruiting | 240 | |
Brain Cancer | Dr. Christine E. Brown | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 82 | |
Blood Cancer Bone Marrow Transplant and Viral Infection |
Michael A. Pulsipher | Children’s Hospital of Los Angeles | Phase 1/2 | Active, not recruiting | 60 | |
Sickle Cell Disease | Dr. De-Fu Zeng | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 3 | |
B cell cancers Leukemia |
Dr. David B. Miklos | Stanford University | Phase 1 | Active, not recruiting | 56 | |
Lung Cancer | Dr. Steven M. Dubinett MD | University of California, Los Angeles | Phase 1 | Active, not recruiting | 24 | |
Cystinosis Kidney Failure |
Dr. Stephanie Cherqui | University of California, San Diego | Phase 1/2 | Active, not recruiting | 6 | |
Parkinson's Disease | Krystof S. Bankiewicz | Brain Neurotherapy Bio | Phase 1 | Active, not recruiting | 11 | |
HIV/AIDS | William Kennedy | Excision BioTherapeutics | Phase 1 | Active, not recruiting | 6 | |
Melanoma | Robert Dillman | Caladrius Biosciences | Phase 3 | Closed | 4 | |
Type 1 diabetes | Howard Foyt | ViaCyte, Inc. | Phase 1/2 | Closed | 19 | |
Melanoma Skin cancer |
Dr. Antoni Ribas MD/PhD | University of California, Los Angeles | Phase 1 | Closed | 5 | |
Heart failure | Dr. Rachel Ruckdeschel Smith | Capricor, Inc | Phase 2 | Closed | 135 | |
Leukemia, Acute Myeloid (AML) | Dr. Colleen Delaney | Nohla Therapeutics Inc | Phase 2 | Closed | 146 | |
Leukemia, Acute Myeloid (AML) | Mark Chao | Forty Seven Inc. | Phase 1 | Closed | 258 | |
Multiple Myeloma | Rajesh Belani MD | Poseida Therapeutics, Inc. | Phase 1 | Closed | 105 | |
Sarcoma | Theodore Scott Nowicki | University of California, Los Angeles | Phase 1 | Closed | 5 | |
Bone or Cartilage Disease | Dr. Gayatri Rao | Rocket Pharmaceuticals, Inc. | Phase 1 | Closed | 1 | |
B cell cancers | Dr. Paul Finnegan | Angiocrine Bioscience, Inc. | Phase 3 | Closed | 130 | |
Blood Cancer | Dr. Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1 | Completed | 10 | |
Amyotrophic Lateral Sclerosis | Dr. Ralph Kern | BrainStorm Cell Therapeutics | Phase 3 | Completed | 196 | |
Spinal Cord Injury | Dr. Jane Stephanie Lebkowski Dr. | Geron Corporation | Phase 1 | Completed | 5 | |
Huntington's Disease | Dr. Vicki Wheelock | University of California, Davis | Phase 1/2 | Completed | 29 | |
Spinal Cord Injury | Francois Binette | Lineage Cell Therapeutics, Inc. | Phase 1/2 | Completed | 25 | |
Stroke | Dr. Bijan Nejadnik | SanBio, Inc. | Phase 2 | Completed | 163 | |
Amyotrophic Lateral Sclerosis | Professor Clive Niels Svendsen | Cedars-Sinai Medical Center | Phase 1/2 | Completed | 18 | |
Retinitis Pigmentosa | Dr. Henry John Klassen | University of California, Irvine | Phase 1/2 | Completed | 28 | |
Retinitis Pigmentosa | Henry John Klassen | jCyte, Inc | Phase 2 | Completed | 84 | |
Genetic Disorder Immune Disease Pediatrics Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Dr. Donald B Kohn Leslie Meltzer Dr. Donald B. Kohn PhD |
University of California, Los Angeles Orchard Therapeutics plc |
Phase 2 | Completed | 10 | |
HIV/AIDS | Geoff Symonds | Calimmune, Inc. | Phase 1/2 | Completed | 13 | |
Blood Cancer | Thomas J Kipps | University of California, San Diego | Phase 1 | Completed | 26 | |
Blood Cancer Solid Tumors |
Professor Irving L Weissman MD | Stanford University | Phase 1 | Completed | 88 | |
Solid Tumors | Dr. Dennis J Slamon | University of California, Los Angeles | Phase 1 | Completed | 46 | |
Colon Cancer | Mark Chao | Forty Seven Inc. | Phase 1/2 | Completed | 78 | |
Osteonecrosis | Nancy E. Lane | University of California, Davis | Phase 1/2 | Completed | 58 | |
Pulmonary Hypertension Vascular Disease |
Dr. Michael I Lewis | Cedars-Sinai Medical Center | Phase 1/2 | Completed | 26 | |
Type 1 diabetes | Dr. William Sietsema | Caladrius Biosciences | Phase 2 | Completed | 113 | |
Heart disease associated with Duchenne muscular dystrophy | Dr. Linda Marban | Capricor, Inc | Phase 2 | Completed | 25 | |
Kidney Failure | Jeffrey Lawson | Humacyte, Inc. | Phase 3 | Completed | 355 | |
Type 1 diabetes | Manasi Jaiman | ViaCyte, Inc. | Phase 1/2 | Completed | 49 | |
Arthritis Osteoarthritis |
Dr. Kristen A Johnson | Calibr | Phase 1 | Completed | 60 | |
Kidney Failure | Daniel Brennan | Medeor Acquisition Corp. | Phase 3 | Completed | 30 | |
Beta Thalassemia | Bettina Cockroft | Sangamo BioSciences, Inc. | Phase 1/2 | Completed | 5 | |
Blood Cancer | Dr. Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1/2 | Completed | 42 | |
Immune Disease Leukocyte Adhesion Deficiency |
Dr. Kinnari Patel | Rocket Pharmaceuticals, Inc. | Phase 1/2 | Completed | 9 | |
Retinitis Pigmentosa | Henry John Klassen | jCyte, Inc | Phase 2 | Completed | 84 | |
COVID-19 | Dr. Michael Matthay MD | University of California, San Francisco | Phase 2 | Completed | 120 | |
Alpha Thalassemia Major | Dr. Tippi C. MacKenzie | University of California, San Francisco | Phase 1 | Enrolling by invitation | 10 | |
Anemia | Dr. Matthew H Porteus | Stanford University | Phase 1/2 | Launching | N/A | |
COVID-19 Respiratory Disorders |
Prof. John A. Zaia | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Amyotrophic Lateral Sclerosis | Clive Svendsen | Cedars-Sinai Medical Center | Phase 1 | Launching | N/A | |
Brain Cancer | Dr Jana Portnow | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Anemia Bone Marrow Transplant and Viral Infection |
Alice Bertaina | Stanford University | Phase 1/2 | Launching | N/A | |
Colon Cancer | Ivan King | Tachyon Therapeutics, Inc | Phase 1 | Launching | N/A | |
Bone or Cartilage Disease Hearing Loss Intellectual Disability Metabolic Disorders Vision Loss |
Dr Robert Hayes | Immusoft Corporation | Phase 1 | Launching | N/A | |
Osteoarthritis | Dr. Thomas W Chalberg Jr. | Genascence Corporation | Phase 1 | Launching | N/A | |
Solid Tumors | Pei Wang | Eureka Therapeutics, Inc. | Phase 1/2 | Launching | N/A | |
Corneal Damage | R. Kim Brazzell | Combangio, Inc. | Phase 2 | Launching | N/A | |
Anemia | Ryotaro Nakamura | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
HIV/AIDS | Dr. Angelo Manuel Almeida Cardoso Ph.D., MD | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Leukemia, Acute Myeloid (AML) | Elizabeth Budde | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Age-related macular degeneration | Dr Jane S Lebkowski | Regenerative Patch Technologies LLC | Phase 2 | Launching | N/A | |
Brain Cancer | Dr. Reena Parada Thomas | Stanford University | Phase 1 | Launching | N/A | |
Neurological Disorders | Amit Etkin | Alto Neuroscience | Phase 2 | Launching | N/A | |
Neurological Disorders Other |
Prof. Olivia Kim-McManus | University of California, San Diego | Phase 1/2 | Launching | N/A | |
Melanoma | Anusha Kalbasi | Stanford University | Phase 1 | Launching | N/A | |
Parkinson's Disease | Dr. Edward Wirth III | Aspen Neuroscience | Phase 1 | Launching | N/A | |
Immune Disease | DR Jonathan Benjamin | ImmPACT-Bio, Inc. | Phase 1/2 | Launching | N/A | |
Brain Cancer | Dr. Hideho Okada | University of California, San Francisco | Phase 1 | Launching | N/A | |
Lupus, Systemic Lupus Erythematosus (SLE) | Bob Valamehr | Fate Therapeutics, Inc. | Phase 1 | Launching | N/A | |
Brain Cancer | Noriyuki Kasahara | University of California, San Francisco | Phase 1 | Launching | N/A | |
Age-related macular degeneration | Dr. Jeffrey H Stern | Luxa Biotechnology | Phase 1/2 | Launching | N/A | |
Solid Tumors | Dr. John Le Gall | Allogene Therapeutics | Phase 1 | Launching | N/A | |
Danon Disease Pediatrics |
Dr. Jonathan Schwartz | Rocket Pharmaceuticals, Inc. | Phase 2 | Launching | N/A | |
Leukemia, Acute Myeloid (AML) | Rochelle Emery | Senti Biosciences, Inc. | Phase 1 | Launching | N/A | |
Blood Disorders | Ilya Rachman MD PhD | Nexcella, Inc. | Phase 1 | Launching | N/A | |
Sickle Cell Disease | Mark C. Walters M.D. | University of California, San Francisco | Phase 1 | Not yet recruiting | 9 | |
Bladder or Urinary Tract Disorder | James Yoo | Wake Forest University Health Sciences | Phase 1 | Not yet recruiting | 10 | |
Immune Disease Pediatrics X-linked Chronic Granulomatous Disease |
Dr. Donald B. Kohn PhD | University of California, Los Angeles | Phase 1/2 | Recruiting | 16 | |
Immune Disease Pediatrics Severe Combined Immunodeficiency, X-linked (X-SCID) |
Dr. Judith A Shizuru Wendy Pang |
Stanford University Jasper Therapeutics, Inc. |
Phase 1/2 | Recruiting | 40 | |
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) | Mort Cowan | University of California, San Francisco | Phase 1 | Recruiting | 25 | |
Kidney Failure | Dr. Everett H. Meyer | Stanford University | Phase 1 | Recruiting | 22 | |
Type 1 diabetes | Peter Stock | University of California, San Francisco | Phase 1/2 | Recruiting | 8 | |
Brain Cancer Breast Cancer |
Dr Saul J Priceman | City of Hope, Beckman Research Institute | Phase 1 | Recruiting | 39 | |
Corneal Damage | Dr. Sophie X Deng | University of California, Los Angeles | Phase 1 | Recruiting | 20 | |
Retinitis Pigmentosa | Clive Svendsen | Cedars-Sinai Medical Center | Phase 1 | Recruiting | 16 | |
HIV/AIDS Immune Disease |
Steven G. Deeks | University of California, San Francisco | Phase 1/2 | Recruiting | 18 | |
Developmental Disorders Spina Bifida |
Dr. Diana L. Farmer | University of California, Davis | Phase 2 | Recruiting | 55 | |
Sickle Cell Disease | David Williams | Boston Children’s Hospital | Phase 2 | Recruiting | 25 | |
Brain Cancer | Dr. Leo D Wang | City of Hope, Beckman Research Institute | Phase 1 | Recruiting | 18 | |
Leukemia, Acute Myeloid (AML) | Joseph Paul Woodard | Immune-Onc Therapeutics | Phase 1 | Recruiting | 106 | |
Stroke | Dr. Gary Steinberg | Stanford University | Phase 1 | Recruiting | 30 | |
Brain Cancer | Crystal Mackall | Stanford University | Phase 1 | Recruiting | 54 | |
B cell cancers Leukemia Leukemia, Acute Myeloid (AML) |
Dr. Matthew H Porteus | Stanford University | Phase 1 | Recruiting | 22 | |
Heart failure | Dr. Joseph C. Wu | Stanford University | Phase 1 | Recruiting | 18 | |
IPEX Syndrome | Dr. Rosa Bacchetta | Stanford University | Phase 1 | Recruiting | 30 | |
Solid Tumors | Dr. Pamela Reilly Contag | BioEclipse Therapeutics INC. | Phase 1 | Recruiting | 60 | |
Epilepsy | Dr. Cory R Nicholas | Neurona Therapeutics | Phase 1 | Recruiting | 40 | |
Muscle Injury | Peter C Belafsky | University of California, Davis | Phase 1/2 | Recruiting | 62 | |
Immune Disease Severe Combined Immunodeficiency, X-linked (X-SCID) |
Stephen Gottschalk | St. Jude Children’s Research Hospital | Phase 1/2 | Suspended | 28 | |
Brain Cancer | Anthony J. Gringeri | ImmunoCellular Therapeutics | Phase 3 | Suspended | 234 | |
Age-related macular degeneration | Dr. Mark S Humayun | University of Southern California | Phase 1 | Unknown status | 16 | |
COVID-19 Respiratory Disorders |
William van der Touw | Celularity Inc. | Phase 1/2 | Unknown status | 86 | |
Sickle Cell Disease | Dr Pierre Caudrelier | ExCellThera Inc. | Phase 1 | Withdrawn | N/A |